论文部分内容阅读
十多年来,大剂量抗坏血酸的使用获得了“可抑制甚至使恶性肿瘤退化”的名声。这一说法出自Ca-meron等人的三篇论文。在研究中,他们选择50名晚期癌病人为一组,每日服10 g抗坏血酸盐,从过去住院治疗癌病人的记录中选1000名作为对照组,两组进行了比较。服用抗坏血酸组平均存活293天,而对照组仅38天。这一惊人的结果中还包括5例癌退化。为此,Mayo诊所的Creagat等人进行了一项前瞻性的随机的双盲法研究,结果服抗坏血酸组(10 g/天)与对照组存活时间一致。Pauling对此结果持异议。他认为在Mayo诊所研究的病人中多数在抗坏血
For more than a decade, the use of high-dose ascorbic acid gained the reputation of “inhibiting or even degenerating malignant tumors.” This statement comes from three papers by Ca-meron et al. In the study, they selected 50 patients with advanced cancer as a group, serving 10 g of ascorbate daily, from the past hospitalized patients with cancer records selected 1000 as a control group, the two groups were compared. The average survival of taking ascorbic acid group 293 days, while the control group only 38 days. This amazing result also includes 5 cases of cancer degeneration. For this reason, Creagat et al. Of the Mayo Clinic conducted a prospective, randomized, double-blind study and found that the ascorbate group (10 g / day) was consistent with the control group. Pauling disagrees with the result. He thinks most of the patients studied at the Mayo Clinic are ascorbic